Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 28586279

Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
N Engl J Med
Publication date
2017 Aug 31
First author
Peters S

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Nat Rev Clin Oncol. 2017 Aug;14(8):457. doi: 10.1038/nrclinonc.2017.99.
    note
    Source null
    related pmid
    28653679
    relationship
    Comment in
  2. citation
    Ann Transl Med. 2017 Nov;5(21):433. doi: 10.21037/atm.2017.08.36.
    note
    Source null
    related pmid
    29201885
    relationship
    Comment in

Authors and identifiers

  1. name
    Peters S
    type
    Author
  2. name
    Camidge DR
    type
    Author
  3. name
    Shaw AT
    type
    Author
  4. name
    Gadgeel S
    type
    Author
  5. name
    Ahn JS
    type
    Author
  6. name
    Kim DW
    type
    Author
  7. name
    Ou SI
    type
    Author
  8. name
    Pérol M
    type
    Author
  9. name
    Dziadziuszko R
    type
    Author
  10. name
    Rosell R
    type
    Author
  11. name
    Zeaiter A
    type
    Author
  12. name
    Mitry E
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Peters S
    type
    Author
  2. name
    Camidge DR
    type
    Author
  3. name
    Shaw AT
    type
    Author
  4. name
    Gadgeel S
    type
    Author
  5. name
    Ahn JS
    type
    Author
  6. name
    Kim DW
    type
    Author
  7. name
    Ou SI
    type
    Author
  8. name
    Pérol M
    type
    Author
  9. name
    Dziadziuszko R
    type
    Author
  10. name
    Rosell R
    type
    Author
  11. name
    Zeaiter A
    type
    Author
  12. name
    Mitry E
    type
    Author
bibliography ids
  1. nci-bib-dccb719ee7a37d7e7e66171d
book metadata
content sha256
ecbb980a96eea1d11060c3e11479038e7c4c42b11d2b4bacdc1cfd87be600215
document type
citation
dois
  1. 10.1056/NEJMoa1704795
electronic publication date
display
2017 Jun 6
precision
day
year
2017
evidence scope
bibliographic_metadata_only
id
pubmed:28586279
immutable id
pubmed:28586279@ecbb980a96eea1d11060c3e11479038e7c4c42b11d2b4bacdc1cfd87be600215
journal
abbreviation
N Engl J Med
issn electronic
1533-4406
issn print
0028-4793
issue
9
name
The New England journal of medicine
nlm unique id
0255562
pages
829-838
volume
377
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Nat Rev Clin Oncol. 2017 Aug;14(8):457. doi: 10.1038/nrclinonc.2017.99.
    note
    Source null
    related pmid
    28653679
    relationship
    Comment in
  2. citation
    Ann Transl Med. 2017 Nov;5(21):433. doi: 10.21037/atm.2017.08.36.
    note
    Source null
    related pmid
    29201885
    relationship
    Comment in
outcomes validated
false
pmid
28586279
provenance
batch id
1c173f0e18be0c6d461b
provider
NCBI PubMed ESummary
record sha256
4ec7ffc117921b46ce75928b42ba31a621b06bccc98d83027744a3a7c065137d
response sha256
27a6f8bb5d49a8d376b07e1b1768913c558986bf73de92cdd65c8f05a5fa1e61
retrieved at
2026-09-09T23:47:25.975513+00:00
publication date
display
2017 Aug 31
precision
day
year
2017
publication types
  1. Clinical Trial, Phase III
  2. Comparative Study
  3. Journal Article
  4. Multicenter Study
  5. Randomized Controlled Trial
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/28586279/
title
Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer.

Preserved source evidence · Not medical advice